These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 19758616)

  • 1. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
    Sun L; Caire AA; Robertson CN; George DJ; Polascik TJ; Maloney KE; Walther PJ; Stackhouse DA; Lack BD; Albala DM; Moul JW
    J Urol; 2009 Nov; 182(5):2242-8. PubMed ID: 19758616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
    Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
    Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
    J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between serum prostate specific antigen level and tumor volume persists in the current era.
    Ochiai A; Troncoso P; Babaian RJ
    J Urol; 2007 Mar; 177(3):903-6. PubMed ID: 17296372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.
    Caire AA; Sun L; Robertson CN; Polascik TJ; Maloney KE; George DJ; Price MM; Stackhouse DA; Lack BD; Albala DM; Moul JW
    Urology; 2010 May; 75(5):1122-7. PubMed ID: 19815259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of prostate gland weight in robot assisted laparoscopic radical prostatectomy.
    Link BA; Nelson R; Josephson DY; Yoshida JS; Crocitto LE; Kawachi MH; Wilson TG
    J Urol; 2008 Sep; 180(3):928-32. PubMed ID: 18635217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
    Sengupta S; Christensen CM; Zincke H; Slezak JM; Leibovich BC; Bergstralh EJ; Myers RP; Blute ML
    J Urol; 2006 Aug; 176(2):559-63. PubMed ID: 16813889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen.
    Isariyawongse BK; Sun L; Bañez LL; Robertson C; Polascik TJ; Maloney K; Donatucci C; Albala D; Mouraviev V; Madden JF; Moul JW
    Urology; 2008 Oct; 72(4):882-6. PubMed ID: 18384857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
    Loeb S; Yu X; Nadler RB; Roehl KA; Han M; Hawkins SA; Catalona WJ
    J Urol; 2007 Jan; 177(1):102-6; discussion 106. PubMed ID: 17162013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
    Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
    BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database.
    Buschemeyer WC; Hamilton RJ; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Freedland SJ
    J Urol; 2008 Jan; 179(1):124-9; discussion 129. PubMed ID: 17997433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?
    Caire AA; Sun L; Ode O; Stackhouse DA; Maloney K; Donatucci C; Mouraviev V; Polascik TJ; Robertson CN; Albala DM; Moul JW
    Urology; 2009 Sep; 74(3):643-7. PubMed ID: 19501891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
    J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing nature of high risk patients undergoing radical prostatectomy.
    Kane CJ; Presti JC; Amling CL; Aronson WJ; Terris MK; Freedland SJ;
    J Urol; 2007 Jan; 177(1):113-7. PubMed ID: 17162017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy.
    Secin FP; Bianco FJ; Vickers AJ; Reuter V; Wheeler T; Fearn PA; Eastham JA; Scardino PT
    Cancer; 2006 Jun; 106(11):2369-75. PubMed ID: 16649221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
    Bañez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
    J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
    Kundu SD; Roehl KA; Yu X; Antenor JA; Suarez BK; Catalona WJ
    J Urol; 2007 Feb; 177(2):505-9. PubMed ID: 17222621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.